Lipoprotein-associated phospholipase A2 (Lp-PLA2) and risk of cardiovascular disease in older adults: Results from the Cardiovascular Health Study

Atherosclerosis

Volumn 209, Issue 2, 2010, Pages 528-532

  Jenny, Nancy Swords ^a   Solomon, Cam ^b   Cushman, Mary ^a   Tracy, Russell P ^a,c   Nelson, Jeanenne J ^d   Psaty, Bruce M ^e   Furberg, Curt D ^f  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d GLAXOSMITHKLINE   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular diseases; Epidemiology; Inflammation; Lipoprotein associated phospholipase A2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HEALTH SURVEY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MYOCARDIAL INFARCTION; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK; STROKE;

EID: 77950021603     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.09.021     Document Type: Article

References (23)

1. Zalewski A., Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005, 25(5):923-931.
2. Kolodgie F.D., Burke A.P., Skorija K.S., et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26(11):2523-2529.
3. Oei H.H., van der Meer I.M., Hofman A., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation 2005, 111(5):570-575.
4. van Vark L.C., Kardys I., Bleumink G.S., et al. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam study. Eur Heart J 2006, 27(19):2346-2352.
5. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 2000, 343(16):1148-1155.
6. Koenig W., Khuseyinova N., Lowel H., Trischler G., Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004, 110(14):1903-1908.
7. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004, 109(7):837-842.
8. Blake G.J., Dada N., Fox J.C., Manson J.E., Ridker P.M. A prospective evaluation of lipoprotein-associated phospholipase A (2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001, 38(5):1302-1306.
9. Persson M., Nilsson J.A., Nelson J.J., Hedblad B., Berglund G. The epidemiology of Lp-PLA (2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 2007, 190(2):388-396.
10. Burke A.P., Farb A., Pestaner J., et al. Traditional risk factors and the incidence of sudden coronary death with and without coronary thrombosis in blacks. Circulation 2002, 105(4):419-424.
11. Fried L.P., Borhani N.O., Enright P., et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991, 1(3):263-276.
12. Cushman M., Cornell E.S., Howard P.R., Bovill E.G., Tracy R.P. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995, 41(2):264-270.
13. Macy E.M., Hayes T.E., Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997, 43(1):52-58.
14. Kardys I., Oei H.H., van der Meer I.M., Hofman A., Breteler M.M., Witteman J.C. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam study. Arterioscler Thromb Vasc Biol 2006, 26(3):631-636.
15. Rothman K.J. Modern epidemiology 1986, Little, Brown, and Company, Boston/Toronto, pp. 317-25.
16. Hosmer D.W., Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992, 3(5):452-456.
17. Daniels L.B., Laughlin G.A., Sarno M.J., Bettencourt R., Wolfert R.L., Barrett-Connor E. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol 2008, 51(9):913-919.
18. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005, 165(21):2479-2484.
19. Jenny N.S., Yanez N.D., Psaty B.M., Kuller L.H., Hirsch C.H., Tracy R.P. Inflammation biomarkers and near-term death in older men. Am J Epidemiol 2007, 165(6):684-695.
20. Stamler J., Daviglus M.L., Garside D.B., Dyer A.R., Greenland P., Neaton J.D. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000, 284(3):311-318.
21. Psaty B.M., Anderson M.S., Kronmal R.A., et al. The association between lipid levels and the risks of incident myocardial infarction, stroke and total mortality: the Cardiovascular Health Study. J Am Geriatr Soc 2004, 52:1639-1647.
22. Ballantyne C., Cushman M., Psaty B., et al. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil 2007, 14(1):3-11.
23. Wolfert R.L., Kim N.W., Selby R.G., Sarno M.J., WarnicK R.G., Sudhir K. Biological variability and specificity of lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel marker of cardiovascular risk. Circulation 2004, 110(Suppl. 3):309.